AU2003218910A1 - Antimicrobial charged polymers that exhibit resistance to lysomal degradation during kidney filtration and renal passage, compositions and method of use thereof - Google Patents

Antimicrobial charged polymers that exhibit resistance to lysomal degradation during kidney filtration and renal passage, compositions and method of use thereof Download PDF

Info

Publication number
AU2003218910A1
AU2003218910A1 AU2003218910A AU2003218910A AU2003218910A1 AU 2003218910 A1 AU2003218910 A1 AU 2003218910A1 AU 2003218910 A AU2003218910 A AU 2003218910A AU 2003218910 A AU2003218910 A AU 2003218910A AU 2003218910 A1 AU2003218910 A1 AU 2003218910A1
Authority
AU
Australia
Prior art keywords
infection
virus
sulfated
polysaccharide
percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003218910A
Other languages
English (en)
Inventor
Wayne D. Comper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monash University filed Critical Monash University
Publication of AU2003218910A1 publication Critical patent/AU2003218910A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
AU2003218910A 2002-08-13 2003-04-24 Antimicrobial charged polymers that exhibit resistance to lysomal degradation during kidney filtration and renal passage, compositions and method of use thereof Abandoned AU2003218910A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40269502P 2002-08-13 2002-08-13
US60/402,695 2002-08-13
US10/321,756 2002-12-17
US10/321,756 US20030181416A1 (en) 2002-01-10 2002-12-17 Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
PCT/AU2003/000488 WO2004014400A1 (en) 2002-08-13 2003-04-24 Antimicrobial charged polymers that exhibit resistance to lysomal degradation during kidney filtration and renal passage, compositions and method of use thereof

Publications (1)

Publication Number Publication Date
AU2003218910A1 true AU2003218910A1 (en) 2004-02-25

Family

ID=31720276

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003218910A Abandoned AU2003218910A1 (en) 2002-08-13 2003-04-24 Antimicrobial charged polymers that exhibit resistance to lysomal degradation during kidney filtration and renal passage, compositions and method of use thereof

Country Status (6)

Country Link
US (2) US20030181416A1 (enExample)
EP (1) EP1534303A4 (enExample)
JP (1) JP2006502129A (enExample)
AU (1) AU2003218910A1 (enExample)
CA (1) CA2495116A1 (enExample)
WO (1) WO2004014400A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171819A1 (en) 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
US7499433B2 (en) * 2002-11-19 2009-03-03 Alcatel-Lucent Usa Inc. Method and apparatus for DTX frame detection
WO2005004882A1 (en) * 2003-07-09 2005-01-20 Monash University Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
ES2251289B1 (es) * 2004-02-27 2007-07-01 Bioiberica, S.A. Nuevo uso terapeutico de un grupo de polisacaridos sulfatados.
US20060154895A1 (en) * 2004-12-09 2006-07-13 Maxwell Gordon Method of treating acquired immunedeficiency syndrome
FR2881051A1 (fr) * 2005-01-27 2006-07-28 Therapol Sa Utilisation de fucanes selectionnes pour la preparation d'un materiau bacteriophobe et bacteriostatique, materiau correspondant et applications
US8721699B2 (en) * 2005-05-13 2014-05-13 Benechill, Inc. Methods and devices for non-invasive cerebral and systemic cooling
US9358150B2 (en) 2005-05-13 2016-06-07 Benechill, Inc. Methods and devices for non-invasive cerebral and systemic cooling alternating liquid mist/gas for induction and gas for maintenance
US7824436B2 (en) * 2005-05-13 2010-11-02 Benechill, Inc. Methods and devices for non-invasive cerebral and systemic cooling
EP1842545A1 (en) * 2006-04-04 2007-10-10 Marinomed Biotechnologie GmbH Anti-inflammatory polymer
US20100160254A1 (en) * 2006-04-04 2010-06-24 Marinomed Biotechnologie Gmbh Cellulose Sulfate for the Treatment of Rhinovirus Infection
US8119780B2 (en) 2006-06-02 2012-02-21 Synedgen, Inc. Chitosan-derivative compounds and methods of controlling microbial populations
US20080248508A1 (en) * 2006-08-17 2008-10-09 Shenda Baker Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin chitosan product derived therefrom and method of accurately determining inflammatory and anti-inflammatory cellular response to such materials
US7981930B2 (en) * 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
PL2178533T3 (pl) 2007-08-24 2013-08-30 Marinomed Biotechnologie Gmbh Kompozycja przeciwwirusowa zawierająca siarczanowany polisacharyd: jota-karagen
WO2010054249A1 (en) * 2008-11-07 2010-05-14 Benechill, Inc. Methods of nasopharyngeal cooling for augmenting coronary perfusion pressure
EP2381951B1 (en) 2009-01-28 2015-12-23 Life Science Nutrition AS Compositions and methods of treating viral infections
CN102802717A (zh) * 2009-06-19 2012-11-28 贝尼奇尔股份有限公司 用于使鼻腔降温的设备
EP3311823B1 (en) * 2009-09-02 2020-11-25 Synedgen, Inc. Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
EP2538946B1 (en) * 2010-02-22 2022-04-06 Marinova Pty Ltd Anti-viral formulations
EP2663338B1 (en) * 2011-01-14 2024-03-06 Emory University Glucose-based oligosaccharides comprising a positron-emitting radionuclide and their use for imaging
US20140046052A1 (en) * 2011-09-21 2014-02-13 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
WO2014036165A1 (en) * 2012-08-29 2014-03-06 Bayer Healthcare, Llc Aqueous based compositions for treating otitis externa
FR2998176B1 (fr) 2012-11-16 2015-01-16 Univ Blaise Pascal Clermont Ii Composition de polysaccharide sulfate
FR3013223B1 (fr) * 2013-11-18 2016-09-02 Amadeite Extrait d'algues pour son utilisation en tant qu'agent anti-bacterien
EP3190886B1 (en) 2014-09-11 2024-04-10 Synedgen, Inc. Compositions for use in the treatment of acute respiratory distress syndrome
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
CN105560983A (zh) * 2016-01-04 2016-05-11 成都富豪斯生物科技有限公司 一种治疗风痰壅盛及头晕目眩的丸剂药物及其制备方法
CN105477011B (zh) * 2016-01-08 2018-02-27 中山大学 卡拉胶Carrageenan在防治猪蓝耳病中的应用
CA3025018C (en) * 2016-05-26 2023-08-29 Griffith University Treatment of alphavirus-induced inflammation
EP3573659A1 (en) * 2017-01-24 2019-12-04 Société des Produits Nestlé S.A. Compositions comprising anti-fel d1 antibodies and methods for reducing at least one symptom of human allergy to cats
CN109820877B (zh) * 2019-04-12 2021-03-30 南华大学 一种构建梅毒螺旋体小鼠模型的方法
CN110663685B (zh) * 2019-10-23 2021-10-12 扬州大学 一种介孔二氧化硅负载ppte的纳米农药制剂
CA3179716A1 (en) 2020-04-09 2021-10-14 Paradigm Biopharmaceuticals Ltd Treatment of acute respiratory distress syndrome (ards) with polysulfated polysaccharides

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE598328A (enExample) * 1959-12-18
US3141014A (en) * 1960-03-31 1964-07-14 Meito Sangyo Kk Sodium and potassium salts of the dextran sulphuric acid ester having substantially no anticoagulant activity but having lipolytic activity and the method of preparation thereof
US3414014A (en) * 1965-03-23 1968-12-03 American & Standard Inc Expansion valve
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3948913A (en) * 1971-04-27 1976-04-06 Ciba-Geigy Corporation New 5-nitrofuryl derivatives
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
ZA791659B (en) * 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
DE3124384C2 (de) * 1981-06-22 1985-05-15 Herbert Prof. Dr. 1000 Berlin Voß Dermatanpolysulfat, Verfahren zu dessen Herstellung und dieses enthaltendes virushemmendes Mittel
US4948881A (en) * 1982-12-28 1990-08-14 Sanofi Process for the depolymerization and sulfation of polysaccharides
US4855416A (en) * 1983-07-25 1989-08-08 Polydex Pharmaceuticals, Ltd Method for the manufacture of dextran sulfate and salts thereof
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8504253D0 (en) * 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3601136A1 (de) * 1986-01-16 1987-07-23 Max Planck Gesellschaft Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
ZA878877B (en) * 1986-11-29 1988-05-24 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Treatment of diseases caused by viruses
EP0285357A3 (en) * 1987-03-31 1989-10-25 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Control of retroviruses
ES2024641B3 (es) * 1987-05-20 1992-03-01 Kk Ueno Seiyaku Oyo Kenkyujo Preservativo.
EP0293826A3 (en) * 1987-06-02 1989-05-10 Stichting REGA V.Z.W. Therapeutic and prophylactic application of sulfated polysaccharides against aids
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
JP2681653B2 (ja) * 1988-05-13 1997-11-26 台糖株式会社 抗エイズウィルス剤
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5272261A (en) * 1989-01-11 1993-12-21 Merrell Dow Pharmaceuticals Inc. Preparation of sulfated polysaccharide fractions
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
CA2013843A1 (en) * 1989-04-06 1990-10-06 Junko Nozaki Antiviral composition
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
FR2657884B1 (fr) * 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
GB9020861D0 (en) * 1990-09-25 1990-11-07 Ml Lab Plc Pharmaceutical compositions
ES2027528A6 (es) * 1990-12-17 1992-06-01 Andromaco Lab Procedimiento para la obtencion de polimeros con actividad antiviral.
AU1052492A (en) * 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent
DE4121389A1 (de) * 1991-02-07 1992-08-13 Nattermann A & Cie Pharmazeutisches produkt zur behandlung von viruserkrankungen
US5221669A (en) * 1991-04-19 1993-06-22 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions containing α-cyclodextrin sulfates alone and in combination with other known antiviral agents and glucocorticoids and methods of treating viral infections
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0664700A1 (en) * 1992-10-13 1995-08-02 Otsuka America Pharmaceutical, Inc. Treatment of cachexia and inhibition of il-6 activity
US5459257A (en) * 1993-01-11 1995-10-17 Dainippon Ink And Chemicals, Inc. Sulfated oligoglycoside acylate and antiviral agent containing the same as active ingredient
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5514665A (en) * 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5594047A (en) * 1995-02-17 1997-01-14 Eastman Kodak Company Method for forming photographic dispersions comprising loaded latex polymers
ZA962077B (en) * 1995-03-14 1997-03-26 Siemens Ag Ultrasonic atomizer device with removable precision dosating unit
ES2177771T3 (es) * 1995-03-14 2002-12-16 Siemens Ag Dispositivo atomizador ultrasonico con unidad desmontable de dosificacion de precision.
US5658893A (en) * 1995-03-29 1997-08-19 Abbott Laboratories Method for inhibition of rotavirus infection with carrageenan
JP3116341B2 (ja) * 1995-04-26 2000-12-11 新神戸電機株式会社 積層板および積層板基材用ガラス織布、ならびに積層板の使用法
US6063773A (en) * 1995-09-29 2000-05-16 Polydex Pharmaceuticals Ltd. Cellulose sulfate for use as antimicrobial and contraceptive agent
US5981509A (en) * 1997-05-20 1999-11-09 Shiseido Company, Ltd. Preparation for prophylaxis or treatment of renal diseases containing sulfated polysaccharide

Also Published As

Publication number Publication date
WO2004014400A1 (en) 2004-02-19
JP2006502129A (ja) 2006-01-19
CA2495116A1 (en) 2004-02-19
EP1534303A1 (en) 2005-06-01
US20060084631A1 (en) 2006-04-20
EP1534303A4 (en) 2008-03-19
US20030181416A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
AU2003218910A1 (en) Antimicrobial charged polymers that exhibit resistance to lysomal degradation during kidney filtration and renal passage, compositions and method of use thereof
US20080004236A1 (en) High Dose, Short Interval Use of Sulfated Polysaccharides for Treatment of Infections
US20050009782A1 (en) Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
US7858637B2 (en) Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
ES2668273T3 (es) Uso de derivados de heparina químicamente modificada en drepanocitosis
CY1119839T1 (el) Στερεες μορφες δοσεως μπενταμουστινης
US20050004071A1 (en) Charged polysaccharides resistant to lysosomal degradation during kidney filtration and renal passage and their use to treat or prevent infection by coronaviruses
US7772206B2 (en) Methods and compositions for the treatment of autoimmune disorders using clofarabine
US20040009953A1 (en) Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
RU2014103800A (ru) Олигосахаридная композиция для предотвращения или снижения риска метаболического синдрома
HU204999B (en) Process for producing pharmaceutical compositions having antiviral activity and comprising synergetic active ingredient combination
JP2015509105A (ja) リファキシミン誘導体及びその使用
CN1688320A (zh) 在肾过滤和肾通道中显示出溶酶体降解抗性的抗微生物带电聚合物、组合物和其使用方法
JP2012526099A5 (enExample)
US20090297478A1 (en) Methods and Compositions for the Treatment of Lupus Using Clofarabine
RU2006101630A (ru) Диамиды аминокислот по положению, не являющемуся положением, полезные в качестве адъювантов для введения биологически активных агентов
CN102858344A (zh) 氘化5,6-二氢-1h-吡啶-2-酮化合物
US20210361696A1 (en) Biologically active combinatorial polysaccharide derivatives
EA042207B1 (ru) Фармацевтическая композиция на основе производных полисахаридов с противовирусным, кровоостанавливающим, регенерирующим действием
JP2004002239A (ja) TNF−α産生抑制剤
WO2009032244A1 (en) Method for the treatment of hiv/aids infection using acyclovir in identified subjects

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application